# US 2022/0034868 A1 · Cardiotoxicity assessment method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034868 A1
- Document ID: US20220034868A1
- Status: Published application
- Kind: A1
- Application number: 17/278,823
- Filed: 2019-08-23
- Published: 2022-02-03
- Earliest claimed: 2018-09-28
- Assignees: Zeon Corporation
- Applicants: Zeon Corporation
- Inventors: Satoru ADACHI; Yuko SEKINO
- Web page: https://patentgrep.com/patent/US20220034868A1

## CPC

- G01N 33/5014: {for testing toxicity}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- G01N 33/5061: {Muscle cells}
- C12N 2503/02: Drug screening
- C12N 2533/30: Synthetic polymers
- G01N 2333/58: Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
- G01N 2500/10: involving cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is a cardiotoxicity assessment method which comprises: seeding cardiomyocytes in a culture container together with a culture medium; adding a drug to the culture medium in the culture container to bring the drug into contact with the cardiomyocytes; and measuring a heart disease biomarker secreted from the cardiomyocytes to assess cardiotoxicity of the drug, wherein at least a culture surface of the culture container is composed of an alicyclic structure-containing polymer, and the culture surface has a surface free energy of 30 to 37 mN/m.

## Claims

### Claim 1

A cardiotoxicity assessment method comprising:
seeding cardiomyocytes in a culture container together with a culture medium;
adding a drug to the culture medium in the culture container to bring the drug into contact with the cardiomyocytes; and
measuring a heart disease biomarker secreted from the cardiomyocytes to assess cardiotoxicity of the drug,
wherein at least a culture surface of the culture container is composed of an alicyclic structure-containing polymer, and the culture surface has a surface free energy of 30 to 37 mN/m.

### Claim 2 (depends on 1)

The cardiotoxicity assessment method according to claim 1, wherein the cardiomyocytes are pluripotent stem cell-derived cardiomyocytes.

### Claim 3 (depends on 1)

The cardiotoxicity assessment method according to claim 1, wherein the heart disease is heart failure and a biomarker of the heart failure is a natriuretic peptide.

### Claim 4 (depends on 1)

The cardiotoxicity assessment method according to claim 1, wherein the alicyclic structure-containing polymer is a hydrogenated norbornene ring-opened polymer.

### Claim 5 (depends on 2)

The cardiotoxicity assessment method according to claim 2, wherein the heart disease is heart failure and a biomarker of the heart failure is a natriuretic peptide.

### Claim 6 (depends on 2)

The cardiotoxicity assessment method according to claim 2, wherein the alicyclic structure-containing polymer is a hydrogenated norbornene ring-opened polymer.

### Claim 7 (depends on 3)

The cardiotoxicity assessment method according to claim 3, wherein the alicyclic structure-containing polymer is a hydrogenated norbornene ring-opened polymer.

### Claim 8 (depends on 5)

The cardiotoxicity assessment method according to claim 5, wherein the alicyclic structure-containing polymer is a hydrogenated norbornene ring-opened polymer.